A Study of Combination Chemotherapy with Gemcitabine(Gemzar) and Cisplatin for Patients with Advanced or Recurrent Cervical Cancer

李子庭,程玺,吴小华,黄啸,臧荣余
DOI: https://doi.org/10.3969/j.issn.1671-170x.2005.04.006
IF: 4.501
2005-01-01
Journal of Oncology
Abstract:[Purpose] To evaluate the clinical response of gemcitabine and cisplatin for patients with advanced or recurrent cervical cancer, and to assess the safety of gemcitabine in combination chemotherapy. [Results] The overall response rate was 47.2%(13/27), including CR, 1 case; PR, 12 cases; NC, 10 cases; and PD, 4 cases. The mean remissive period was 7.2 months. The main toxicity was marrow suppression. The rate of leukocytopenia and thrombocytopenia with Ⅲ to Ⅳ degree was 37.1% and 25.9% respectively. No severe complications happened. [Conclusions] Combined gemcitabine with cisplatin is effective in patients with advanced or recurrent cervical cancer. The two agents have synergetic effect. The use of combined gemcitabine and cisplatin produces higher response rate with mild and well tolerated toxicity.
What problem does this paper attempt to address?